For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?

Amit G. Singal; George N. Ioannou

doi:10.1016/j.cgh.2019.02.020

For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	1732-1735
Number of pages	4
Journal	Clinical Gastroenterology and Hepatology
Volume	17
Issue number	9
DOIs	https://doi.org/10.1016/j.cgh.2019.02.020
State	Published - Aug 2019

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/j.cgh.2019.02.020

Cite this

@article{ad2163846544466d97dfbe18e2333754,

title = "For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?",

author = "Singal, {Amit G.} and Ioannou, {George N.}",

note = "Funding Information: Conflicts of interest This author discloses the following: Dr Singal has been on advisory boards and served as a consultant for Wako Diagnostics, Roche, Exact Sciences, and Glycotest and has received research funding from AbbVie and Gilead. The remaining author discloses no conflicts. Funding Dr Singal's research is supported in part by NCI R01 CA222900. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Veterans Administration or the National Institutes of Health.",

year = "2019",

month = aug,

doi = "10.1016/j.cgh.2019.02.020",

language = "English (US)",

volume = "17",

pages = "1732--1735",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",